Trial met its primary endpoint, with 64.3% of patients self-administering etripamil converting to sinus rhythm within 30 minutes compared to 31.2% on placebo (HR = 2.62, p<0.001)
─ Consistent safety and tolerability data support potential self-administration of etripamil
─ Analyses of pooled data show statistically significant reduction in medical interventions and visits to the emergency department
─ Company plans to submit an NDA to the U.S. FDA in mid-2023
─ Conference call and webcast to be held today at 8:00 a.m. Eastern Time
Milestone will host a conference call and webcast to discuss the results of the RAPID trial today, October 17, 2022 at 8:00 a.m. ET. To access the live call by phone, dial (877) 870-4263 (domestic) or (412) 317-0790 (international); the conference ID is 10171280. A live audio webcast of the event and accompanying slides may also be accessed through the "Investors" section of Milestone's website at www.milestonepharma.com. A replay of the webcast will be available for one year following the event.
https://finance.yahoo.com/news/milestone-pharmaceuticals-announces-positive-results-100000485.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.